Medicenna Therapeutics (TSE:MDNA) Stock Price Down 1.1% – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA) fell 1.1% during trading on Tuesday . The stock traded as low as C$0.83 and last traded at C$0.87. 26,254 shares were traded during trading, a decline of 77% from the average session volume of 112,271 shares. The stock had previously closed at C$0.88.

Medicenna Therapeutics Trading Down 5.6%

The stock has a 50 day moving average of C$0.90 and a 200-day moving average of C$1.09. The company has a market capitalization of C$70.07 million, a P/E ratio of -5.60 and a beta of 2.87. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last issued its quarterly earnings data on Thursday, February 12th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, research analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.